Detalhe da pesquisa
1.
BET bromodomain inhibitors regulate keratinocyte plasticity.
Nat Chem Biol
; 17(3): 280-290, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462494
2.
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Bioorg Med Chem Lett
; 59: 128577, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065232
3.
Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Angew Chem Int Ed Engl
; 61(46): e202117276, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36257909
4.
Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices.
Respir Res
; 20(1): 111, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31170998
5.
Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation.
BMC Nephrol
; 20(1): 147, 2019 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31035960
6.
Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
Chimia (Aarau)
; 73(7): 561-570, 2019 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31431216
7.
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Biochemistry
; 57(38): 5576-5590, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30148617
8.
Imatinib relaxes the pulmonary venous bed of guinea pigs.
Respir Res
; 18(1): 32, 2017 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28178968
9.
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.
Nature
; 463(7280): 501-6, 2010 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20072125
10.
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer
; 7(5): 345-56, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17457302
11.
Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro.
J Neurooncol
; 116(2): 231-6, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24173684
12.
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Acta Haematol
; 132(1): 75-86, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504330
13.
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".
Biochemistry
; 57(5): 477-478, 2018 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188995
14.
The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Bioorg Med Chem
; 21(11): 3231-9, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23611771
15.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell
; 7(2): 129-41, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15710326
16.
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood
; 115(21): 4206-16, 2010 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20299508
17.
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.
Haematologica
; 97(6): 907-14, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22207690
18.
Erratum to: Imatinib relaxes the pulmonary venous bed of guinea pigs.
Respir Res
; 18(1): 121, 2017 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28629421
19.
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Cancer Cell
; 1(5): 433-43, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12124173
20.
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Cancer Cell
; 3(5): 459-69, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12781364